• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Critical Review of Data Helps Trim Polypharmacy Regimens

Article

Closer examination of claims about benefits and risks of blockbuster drugs may reveal a lack of evidence to support such widespread use, Thomas E. Finucane, MD, professor of medicine, Johns Hopkins University, Baltimore, told attendees at the American College of Physicians Annual Session here.

Closer examination of claims about benefits and risks of blockbuster drugs may reveal a lack of evidence to support such widespread use, Thomas E. Finucane, MD, professor of medicine, Johns Hopkins University, Baltimore, told attendees at the American College of Physicians Annual Session here.

"We have to keep in mind that we are dealing with an industry that has a goal of making money for its stockholders while our focus is on taking the best care of our patients. Build a wall around yourselves as you are bombarded with promotional information, and remain skeptical and vigilant," said Finucane.

Finucane provided a number of examples where he sees problems with overprescribing occurring as a mismatch between marketing claims and existing evidence. Part of the issue is that even the peer-reviewed literature is contaminated, he said. Not only are positive trials far more likely to be submitted for publication than negative trials, but the published literature is filled with industry-sponsored studies and the discussions in the papers are often filled with rhetoric unrelated to the scientific findings.

Furthermore, Finucane said, while highly regarded opinion leaders in a field may appear as the author of those papers, the manuscript itself may have been written internally and the author sought secondarily.

Finucane presented more critical reviews of the evidence for the efficacy and safety of proton pump inhibitors, selective serotonin reuptake inhibitors, gabapentin, newer hypnotic agents, newer drugs for overactive bladders, acetylcholinesterase inhibitors, and COX-2 inhibitors that might lead physicians to rethink their prescribing patterns for those medications.

He also recommended a number of websites that are good sources for unbiased information:
www.fda.gov/medwatch

www.medicalletter.org

www.nofreelunch.org

www.citizen.org/hrg

www.nice.org.uk

Related Videos